About CLINUVEL

Company snapshot

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). In June 2018 CLINUVEL submitted a new drug application with the US FDA seeking marketing authorisation for SCENESSE®. More information on EPP can be found at http://www.epp.care

Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore.

Click here to read the CLINUVEL Investor Summary.

 

 

Facts

ASX Listed

Shares on Issue

Conditional performance rights

52 week price range (17/09/2018)

Market cap (17/09/2018)

2001

47,857,986

1,750,560

$6.40 - $18.89

A$867.67m

Locations

Melbourne, Australia
Zug, Switzerland
Leatherhead, UK
Singapore

www.clinuvel.com

Company headquarters
Swiss operational office
UK operational office
Asian operational office

Stock listings

ASX

Xetra-DAX

Level 1 ADR

CUV

UR9

CLVLY

Finances

Cash at bank (01/06/2018)
Total revenues and reimbursements received (2017/18 FY)
PBIT (2017/18 FY)
Increase in Net Cash provided by (Used in) Operating Activities (2017/18 FY)

A$36.19m
A$25.7m

A$12.9m
A$11.7m

Products

SCENESSE® (afamelanotide 16mg implant)

 


CUV9900

VLRX001

First-in-class photoprotective and repigmentation drug with EMA approval for rare disease EPP, NDA submitted to US FDA. Phase IIb trial ongoing in Singapore for vitiligo

Alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogues in early development

People

Stan McLiesh

Dr Philippe Wolgen

Brenda Shanahan

Willem Blijdorp
Dr Karen Agersborg

Dr Dennis Wright

Darren Keamy

Non-Executive Chair

CEO, Director

Non-Executive Director

Non-Executive Director

Non-Executive Director

Acting Chief Scientific Officer

CFO, Company Secretary

Contact

General

Investors

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Last updated: 17 September 2018